FDA grants approval to ivacaftor for treatment of cystic fibrosis in infants
Written By : Medha Baranwal
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2020-10-06 12:00 GMT | Update On 2020-10-07 07:24 GMT
Advertisement
USA: The US Food and Drug Administration (FDA) has given approval to ivacaftor for treatment of cystic fibrosis in infants aged four months to less than six months who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Kalydeco (ivacaftor) is already approved by the FDA for treating cystic fibrosis in patients aged 6 months and older.
"Initiating therapy that treats the underlying cause of cystic fibrosis as early as four months of age may have the potential to modify the course of the disease," said Margaret Rosenfeld, M.D., MPH, Seattle Children's Research Institute and Department of Pediatrics, University of Washington School of Medicine.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.